The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 350 participants.

Also called NCT05579418

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 350 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05579418
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05579418. Randomized; no masking; primary purpose treatment. Start 2022-11-01 (anticipated); primary completion 2024-10-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients
Condition
STEMI
Condition
Dyslipidemias
Intervention (Drug)
Evolocumab
Lead sponsor
Hamad Medical Corporation (class: industry)

Record details

Record id
cardio:ct-nct05579418
Content hash
ff8b819cab7b78c1c240799fa333ca231994d0e35ae7b0a982407095c33ce56f